Microarray testing as an efficient tool to redefine hyperdiploid paediatric B-cell precursor acute lymphoblastic leukaemia patients.
Adolescent
Child
Child, Preschool
Chromosomes, Human
/ genetics
Female
Follow-Up Studies
Gene Dosage
Humans
Infant
Loss of Heterozygosity
Male
Neoplasm Proteins
/ genetics
Oligonucleotide Array Sequence Analysis
Ploidies
Polymorphism, Single Nucleotide
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
Acute lymphoblastic leukaemia
Children
High hyperdiploid BCP- ALL
Microarray
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
05
02
2019
revised:
24
05
2019
accepted:
25
05
2019
pubmed:
16
6
2019
medline:
21
5
2020
entrez:
16
6
2019
Statut:
ppublish
Résumé
The aim of our study was to characterize genetic alterations in a cohort of paediatric patients with B-cell progenitors (BCP-ALL) and a hyperdiploid karyotype. In our study, we analysed 55 childhood hyperdiploid BCP-ALL patients using single nucleotide polymorphism (SNP) microarray testing. The group consisted mostly of patients with the modal number of chromosomes between 54 and 58 (34 cases). Within this group, Trisomy 4 and Trisomy 10 (30 cases) were the most frequent cases. Additionally, a total of 93 structural abnormalities mainly affecting chromosomes 1, 6, 9, 12, and 17 as well as 68 copy number alterations (CNAs) were identified. The microarray testing revealed a loss of ETV6, IKZF1, CDKN2A/CDKN2B, PAX5, and RB1. Moreover, chromosomal abnormalities resulting in the loss of heterozygosity (LOH) were also observed. Currently, patients with hyperdiploidy constitute a genetically heterogeneous group, and therefore, it is insufficient to rely only on banding cytogenetic analysis for the identification of hyperdiploid karyotype. Microarray testing has been proven an effective and satisfactory tool for the analysis of molecular karyotypes and to redefine the prognostic criteria in hyperdiploid patients.
Identifiants
pubmed: 31202078
pii: S0145-2126(19)30101-8
doi: 10.1016/j.leukres.2019.05.013
pii:
doi:
Substances chimiques
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106163Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.